Proviral Sequencing Driven Development of Enhanced IPDAv2 with Global HIV-1 Group M Coverage to Support Worldwide Cure and Clinical Trials

Proviral 测序驱动增强型 IPDAv2 的开发，覆盖全球 HIV-1 M 组，以支持全球治疗和临床试验

• 批准号: 10927086
• 负责人: GREGORY LAIRD
• 金额: $ 200万
• 依托单位: ACCELEVIR DIAGNOSTICS, LLC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10927086
• 关键词: Base Sequence; Biological Assay; Clinical; Clinical Research; Clinical Trials; Contracts; Development; Genetic Transcription; Goals; HIV; HIV-1; Intervention; Length; Monitor; Proviruses; Recombinants; analytical tool; commercialization; design; programs; prospective

The objective of this program is to develop and commercialize sequence-based HIV reservoir assays for clinical HIV cure interventions. The assay should be designed as an analytical tool to monitor the size of the replication-competent HIV reservoir in clinical research and in prospective clinical trials. An additional goal of the program is to develop secondary assays that are not tissue culture-based and discriminate between actively transcribed and latent full-length proviruses. This contract is to develop and validate version 2 of the IPDA for use across major HIV-1 Group M subtypes and recombinants.

该计划的目标是开发和商业化用于临床艾滋病毒治愈干预的基于序列的艾滋病毒储存分析。在临床研究和前瞻性临床试验中，应将该检测设计为一种分析工具，以监测具有复制能力的艾滋病毒储存库的大小。该计划的另一个目标是开发不以组织培养为基础的二级分析，并区分活跃转录的全长前病毒和潜伏的全长前病毒。这份合同是为了开发和验证IPDA版本2，以用于主要的HIV-1组M亚型和重组体。